nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2024 | editorial

Molecular tumor board—editorial

verfasst von: Priv. Doz. Dr. Hossein Taghizadeh, Prof. Dr. Armin Gerger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Excerpt

Precision oncology is transforming the landscape of cancer treatment by leveraging molecular profiling techniques to tailor therapeutic strategies to the unique genetic makeup of each patient’s disease. Two recent articles delve into critical aspects of this evolving field: the role of molecular tumor boards (MTBs) and the integration of liquid biopsies into clinical practice. …

Vorheriger Artikel ASH 2023

Nächster Artikel Antibody–drug conjugates (ADC special)—part 2

Boos LA, Wicki A. The molecular tumorboard—a key element of precision oncology. memo. 2024; https://doi.org/10.1007/s12254-024-00977-7.CrossRef

Hasenleitner SOP, Heitzer E. Liquid profiling for patients with advanced cancer is ready for clinical integration. memo. 2024; https://doi.org/10.1007/s12254-024-00978-6.CrossRef

Titel: Molecular tumor board—editorial
verfasst von: Priv. Doz. Dr. Hossein Taghizadeh
Prof. Dr. Armin Gerger
Publikationsdatum: 01.09.2024
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-024-00989-3

Emerging drugs in breast cancer: a focus on antibody–drug conjugates and novel treatment options in luminal disease

Open Access
Short Review

Antibody–drug conjugates (ADCs) in lung cancer treatment

Open Access
short review

Importance of allogeneic stem cell transplantation in myelofibrosis

Open Access
short review

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Open Access
review

Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023

Open Access
short review

Antibody–drug conjugates (ADC special)—part 2

editorial

Springer Medizin Österreich

Molecular tumor board—editorial

Excerpt

Weitere Artikel der Ausgabe 3/2024

Emerging drugs in breast cancer: a focus on antibody–drug conjugates and novel treatment options in luminal disease

Antibody–drug conjugates (ADCs) in lung cancer treatment

Importance of allogeneic stem cell transplantation in myelofibrosis

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023

Antibody–drug conjugates (ADC special)—part 2

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Emerging drugs in breast cancer: a focus on antibody–drug conjugates and novel treatment options in luminal disease

Antibody–drug conjugates (ADCs) in lung cancer treatment

Importance of allogeneic stem cell transplantation in myelofibrosis

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023

Antibody–drug conjugates (ADC special)—part 2